Ximang Medical Secures Tens of Millions in Angel and Angel+ Funding to Advance Brain-Computer Interface Innovation and Clinical Applications

VCBeat learned第一时间that a cutting-edge brain-computer interface company focusing on rapid clinical application research and developmentAciMicroRecently completed tens of millions of yuan in angel round and angel+ round financing. This round of financing was led byGuangzhou Tongxin Fund, Pingyun Innovation Fund, Shenzhen Huibo Growth Venture Capital Corporation, Guangzhou Venture Capital Mother Fund, Yuanqi Science and Technology Innovation (Beijing) Fund Management Co., Ltd., Beijing-Tianjin-Hebei Technology Innovation Center, Guangdong Collaborative Innovation HoldingsCo-investment, the raised funds will be mainly used to promote the research and development of brain-computer interface medical devices and key components, as well as clinical trials, device registration, market promotion, and talent team building.

Brain-computer interface (BCI) is a hot area in the current international science and technology innovation development. Against the backdrop of transformative advancements in human-computer interaction technology, its application potential is enormous. Particularly in clinical applications, BCI technology has significant room for development in advancing human health and enhancing brain-like intelligence. It plays a crucial role in treating neurological diseases, promoting patient rehabilitation, and improving quality of life. Precisely because of this, BCI technology has also become a "strategic high ground" in global technological competition.

According to McKinsey's estimates, the potential market size of global brain-computer interface medical applications is expected to reach 40 billion US dollars by 2030, and is projected to exceed 145 billion US dollars by 2040. With continuous breakthroughs in brain-computer interface technology and the gradual expansion of application scenarios, it is foreseeable that this field will experience explosive growth in the next ten to twenty years.

The 2024 Government Work Report for the first time proposed "new quality productive forces" and "artificial intelligence +", identifying brain-computer interface as a significant representative of future industries, highlighting its crucial role in promoting industrial innovation and high-quality development.

2025 is considered a pivotal year for the commercialization of brain-computer interface technology, which is expected to see scaled applications and commercial mass production.

• On January 8, 2025, the Beijing Municipal Science and Technology Commission and others issued the "Action Plan for Accelerating the Innovative Development of Brain-Computer Interface in Beijing (2025-2030)", proposing that by 2027, major original achievements will be produced, and key core technologies will be broken through. The plan aims to cultivate 3-5 potential unicorn and unicorn enterprises with core competitiveness, establish 2-3 product feature experience and exhibition centers, and accelerate the implementation of brain-computer interface technology in multi-scenario applications.

• On January 10, the Shanghai Science and Technology Commission issued the "Shanghai Brain-Computer Interface Future Industry Cultivation Action Plan (2025-2030)." It proposed that by 2027, high-quality brain control will be achieved, semi-invasive brain-computer interface products will be the first to achieve clinical application in China, breakthroughs will be made in invasive brain-computer interface research and development, and an initial innovative ecosystem for brain-computer interfaces will be established. By 2030, brain-computer interface products will achieve full clinical application, establishing a global innovation hub for brain-computer interface products, with core aspects of the industrial chain achieving self-control.

As Beijing, Shanghai and other places have密集issued brain-computer interface development policies, China's commercialization process in this technology field is accelerating.

  AciMicro Intracranial Implantable Electrode Array

The core founding team of AciMicro Medical is composed of multidisciplinary cross-technology experts from Peking University, with profound academic backgrounds and R&D experience in micro devices, biochips, and neuroscience. They possess key brain-computer interface technologies such as implantable neural electrodes and dedicated neural signal processing systems, focusing on providing cutting-edge medical solutions for patients with neurological dysfunction and nerve injuries. The AciMicro team already holds more than ten authorized core technology invention patents and one Class II medical device registration certificate.

AciMicro's medical-grade products focus on neurofunctional disorder solutions, comprehensively covering the full range of instruments and equipment for the diagnosis and treatment of neurological diseases.The implantable brain-computer interface system is AciMicro's core scientific research-grade product, which was successfully selected for the first batch of the Ministry of Science and Technology's National Key R&D Plan Disruptive Technology Innovation Special Support in 2022.

μNeurode Series Implantable Microelectrodes Utilize Cutting-Edge Neural Interface Design and Manufacturing Technology, Reducing Microelectrode Contacts to the Size of Individual Neurons, Breaking Through the Fundamental Core Technology Barrier of Implantable Brain-Computer Interfaces.It is a domestically首创 product that can rival and replace the American Utah electrode.

AciMicro Medical Implantable Neural Electrode Array and Spike Signal Acquisition

At the same time, due to differences in materials and manufacturing processes, the μNeurode series of implantable microelectrodes have significant advantages in terms of flexibility, mechanical strength, customizability, and production efficiency.And pioneered the flexible substrate electrode array。

The μNeurode series of implantable microelectrodes are widely suitable for in vivo electrophysiological studies, both acute and chronic, in small animals, medium to large animals, and non-human primates. They interconnect with standard connectors and are compatible with the majority of multi-channel electrophysiological instruments available on the market, meeting the diverse needs of different research users.AciMicro's implantable brain-computer interface system has already launched large-scale animal trials across multiple species and pre-clinical research.

AciMicro Medical will follow the development path from scientific research products to clinical medical products, integrate brain-computer interface (BCI) technology into clinical applications, establish a strong product market, gradually expand its scale, and strive to become an industry leader. AciMicro Medical will also maintain an open attitude, collaborating with experts, scholars, and various talents in the fields of neuroscience, brain-computer interfaces, and biomedicine, to fully commit to advancing breakthroughs in BCI technology, accelerating the clinical application and industrial development of BCI.